Anika Therapeutics, Inc.

NasdaqGS:ANIK Stock Report

Market Cap: US$233.0m

Anika Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Anika Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

3.0%

Buyback Yield

Total Shareholder Yield3.0%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

Recent updates

Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet

Dec 19
Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Jan 30
Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth

Aug 03
Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth

Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity

Mar 11

Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

Jun 25
Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

Anika Therapeutics (ANIK) Presents At UBS Global Healthcare Virtual Conference - Slideshow

May 28

Anika Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Mar 16
How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly

Feb 09
Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly

An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued

Jan 13
An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued

If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%

Dec 18
If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%

Anika Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ANIK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANIK's dividend payments have been increasing.


Dividend Yield vs Market

Anika Therapeutics Dividend Yield vs Market
How does ANIK dividend yield compare to the market?
SegmentDividend Yield
Company (ANIK)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.7%
Industry Average (Biotechs)1.7%
Analyst forecast (ANIK) (up to 3 years)n/a

Notable Dividend: Unable to evaluate ANIK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANIK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ANIK's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ANIK has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/16 15:36
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Anika Therapeutics, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PetuskyBarrington Research Associates, Inc.
Mark LandyNorthland Capital Markets
James SidotiSidoti & Company, LLC